S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

IM Cannabis (IMCC) Competitors

$0.56
+0.05 (+9.74%)
(As of 04/17/2024 ET)

IMCC vs. MTEX, NURO, GRAY, HSCS, GBS, SYRA, IBIO, CHRO, CELZ, and TENX

Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Mannatech (MTEX), NeuroMetrix (NURO), Graybug Vision (GRAY), Heart Test Laboratories (HSCS), GBS (GBS), Syra Health (SYRA), iBio (IBIO), Chromocell Therapeutics (CHRO), Creative Medical Technology (CELZ), and Tenax Therapeutics (TENX). These companies are all part of the "medical" sector.

IM Cannabis vs.

Mannatech (NASDAQ:MTEX) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Mannatech has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

In the previous week, Mannatech and Mannatech both had 1 articles in the media. IM Cannabis' average media sentiment score of 0.50 beat Mannatech's score of -0.50 indicating that Mannatech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 53.1% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
IM Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Mannatech received 273 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 74.60% of users gave Mannatech an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.

CompanyUnderperformOutperform
MannatechOutperform Votes
279
74.60%
Underperform Votes
95
25.40%
IM CannabisOutperform Votes
6
42.86%
Underperform Votes
8
57.14%

Mannatech has higher revenue and earnings than IM Cannabis. Mannatech is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$131.96M0.12-$2.24M-$1.20-6.95
IM Cannabis$36.15M0.21-$7.04M-$0.47-1.20

Mannatech has a net margin of -1.70% compared to Mannatech's net margin of -16.42%. IM Cannabis' return on equity of -19.19% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-1.70% -19.19% -4.99%
IM Cannabis -16.42%-44.25%-16.48%

Summary

Mannatech beats IM Cannabis on 11 of the 14 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

MetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$7.54M$1.25B$4.76B$7.41B
Dividend YieldN/A2.35%5.42%3.97%
P/E Ratio-1.206.61255.8418.47
Price / Sales0.2110.302,450.3087.81
Price / CashN/A166.8047.8235.32
Price / Book0.742.374.624.20
Net Income-$7.04M-$165.28M$101.98M$212.26M
7 Day Performance-23.79%-6.37%-4.70%-4.42%
1 Month Performance52.57%4.95%-4.45%-3.47%
1 Year Performance-22.71%7.77%10.13%4.35%

IM Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEX
Mannatech
0 of 5 stars
$8.50
flat
N/A-45.2%$15.98M$131.96M-7.08228Analyst Report
News Coverage
NURO
NeuroMetrix
0 of 5 stars
$3.51
-0.3%
N/A-69.1%$6.99M$5.90M-0.5626
GRAY
Graybug Vision
0 of 5 stars
$4.34
-1.1%
N/A+27.3%$6.82MN/A-2.5127Gap Up
High Trading Volume
HSCS
Heart Test Laboratories
0 of 5 stars
$0.10
flat
N/A-90.3%$6.82MN/A-0.2212
GBS
GBS
0 of 5 stars
$2.94
-9.8%
N/A+2.4%$7.05M$440,000.00-5.257Gap Down
SYRA
Syra Health
0 of 5 stars
$1.23
flat
N/AN/A$7.05M$5.51M0.0078Negative News
IBIO
iBio
0 of 5 stars
$1.95
+1.0%
N/AN/A$6.79M$2.38M0.0026
CHRO
Chromocell Therapeutics
0 of 5 stars
$1.82
-6.7%
N/AN/A$7.06MN/A0.003Gap Down
CELZ
Creative Medical Technology
0 of 5 stars
$5.20
-0.2%
N/A-26.6%$7.07M$10,000.00-1.404Positive News
TENX
Tenax Therapeutics
1.8104 of 5 stars
$3.61
flat
$480.00
+13,196.4%
-87.7%$7.08MN/A0.007Gap Up

Related Companies and Tools

This page (NASDAQ:IMCC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners